WMS Partners’s AbbVie ABBV Stock Holding History

WMS Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,365	Closed	-$2.2M	–	2
2024 Q4	$2.2M	Buy	12,365 +407	+3%	+$74.8K	0.12%	73
2024 Q3	$2.36M	Buy	11,958 +4,489	+60%	+$838K	0.13%	67
2024 Q2	$1.28M	Buy	7,469 +111	+2%	+$18.4K	0.08%	90
2024 Q1	$1.34M	Sell	7,358 -390	-5%	-$67.2K	0.09%	92
2023 Q4	$1.2M	Sell	7,748 -3,248	-30%	-$474K	0.09%	93
2023 Q3	$1.64M	Sell	10,996 -1,038	-9%	-$152K	0.13%	74
2023 Q2	$1.62M	Sell	12,034 -128	-1%	-$18.8K	0.13%	73
2023 Q1	$1.94M	Sell	12,162 -441	-3%	-$67.4K	0.17%	60
2022 Q4	$2.04M	Sell	12,603 -208	-2%	-$31.9K	0.2%	56
2022 Q3	$1.72M	Sell	12,811 -24	-0.2%	-$3.44K	0.23%	54
2022 Q2	$1.97M	Buy	12,835 +170	+1%	+$26K	0.31%	51
2022 Q1	$2.05M	Sell	12,665 -330	-3%	-$47.9K	0.28%	48
2021 Q4	$1.76M	Sell	12,995 -129	-1%	-$15.2K	0.38%	48
2021 Q3	$1.42M	Sell	13,124 -251	-2%	-$28.7K	0.21%	63
2021 Q2	$1.51M	Sell	13,375 -171	-1%	-$19.3K	0.22%	55
2021 Q1	$1.47M	Buy	13,546 +32	+0.2%	+$3.42K	0.33%	50
2020 Q4	$1.45M	Sell	13,514 -10	-0.1%	-$961	0.25%	53
2020 Q3	$1.19M	Sell	13,524 -595	-4%	-$56K	0.23%	57
2020 Q2	$1.39M	Buy	14,119 +2,582	+22%	+$227K	0.29%	52
2020 Q1	$879K	Sell	11,537 -850	-7%	-$72.4K	0.24%	57
2019 Q4	$1.1M	Sell	12,387 -410	-3%	-$34K	0.25%	60
2019 Q3	$969K	Sell	12,797 -1,635	-11%	-$112K	0.23%	59
2019 Q2	$1.05M	Buy	14,432 +1,680	+13%	+$132K	0.26%	58
2019 Q1	$1.03M	Buy	12,752 +1,010	+9%	+$82.6K	0.26%	59
2018 Q4	$1.08M	Sell	11,742 -283	-2%	-$24.9K	0.3%	51
2018 Q3	$1.14M	Sell	12,025 -135	-1%	-$12.8K	0.13%	72
2018 Q2	$1.13M	Buy	12,160 +2,577	+27%	+$252K	0.13%	73
2018 Q1	$907K	Sell	9,583 -124	-1%	-$13.6K	0.11%	77
2017 Q4	$939K	Buy	9,707 +238	+3%	+$22.4K	0.11%	83
2017 Q3	$841K	Sell	9,469 -200	-2%	-$15.2K	0.1%	85
2017 Q2	$701K	Buy	9,669 +1,522	+19%	+$102K	0.09%	95
2017 Q1	$531K	Sell	8,147 -1,048	-11%	-$65.9K	0.07%	109
2016 Q4	$576K	Sell	9,195 -246	-3%	-$15K	0.08%	101
2016 Q3	$595K	Buy	9,441 +1,100	+13%	+$71.2K	0.08%	100
2016 Q2	$516K	Sell	8,341 -2,210	-21%	-$135K	0.07%	107
2016 Q1	$603K	Sell	10,551 -1,574	-13%	-$87.7K	0.08%	103
2015 Q4	$718K	Buy	12,125 +1,774	+17%	+$102K	0.1%	95
2015 Q3	$563K	Sell	10,351 -8,261	-44%	-$538K	0.09%	102
2015 Q2	$1.25M	Buy	18,612 +252	+1%	+$16.5K	0.15%	109
2015 Q1	$1.07M	Buy	18,360 +7,888	+75%	+$477K	0.13%	115
2014 Q4	$685K	Sell	10,472 -608	-5%	-$38.3K	0.11%	97
2014 Q3	$640K	Sell	11,080 -1,650	-13%	-$91.6K	0.1%	122
2014 Q2	$719K	Sell	12,730 -25,620	-67%	-$1.34M	0.11%	110
2014 Q1	$1.97M	Sell	38,350 -8,081	-17%	-$408K	0.32%	59
2013 Q4	$2.45M	Sell	46,431 -28,669	-38%	-$1.41M	0.4%	56
2013 Q3	$3.36M	Sell	75,100 -860	-1%	-$38.1K	0.64%	43
2013 Q2	$3.14M	Buy	+75,960	New	+$3.32M	0.57%	49

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

WMS Partners's ABBV Position: Q1 2025 in Review

WMS Partners sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 12,365 shares — an estimated $2.2M sold.

WMS Partners first reported a position in ABBV in Q2 2013 and held it in 47 quarters. The position peaked at $3.36M in Q3 2013. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

WMS Partners reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
WMS Partners sold 12,365 AbbVie shares in Q1 2025, an estimated $2.2M.
WMS Partners first reported a position in AbbVie in Q2 2013 and held it in 47 quarters.
WMS Partners's AbbVie position peaked at $3.36M in Q3 2013.
3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on WMS Partners's 13F filing for Q1 2025.